Skip to content
value.today

Echo Therapeutics, Inc.

Formerly SONTRA MEDICAL CORP, CHOICETEL COMMUNICATIONS INC/MN/, SONTRA MEDICAL CORP

Total raised
$26 M
7 rounds on record
Latest round
$2 M
Jan 2016
First round on record
Jul 2009
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Echo Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2016$2 MNo. 7Under $2 million

Echo Therapeutics, Inc.: Raise no. 7, Jan 2016

Investors in this round

15 investors had bought by the notice of Feb 8, 2016: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Echo Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $6 M offered; $4 M still to sell
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$145,500
Finders' fees
none
Paid to its own people
$200,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan W. Schoenbart · Executive Officer
  • Scott W. Hollander · Executive Officer, Director
  • Elazer R. Edelman · Director
  • Michael M. Goldberg · Director
  • Shepard M. Goldberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Newbridge Securities Corporation (CRD 104065) · Boca Raton, FloridaSold in CA, CT, IL, MA, NJ, NY, SC, TX

Remarks in the notice

  • On fees: “+ 8% warrants”
  • On the use of proceeds: “Amount owed to executive officers for unpaid compensation.”

Signed by Alan W. Schoenbart, Cfo. Source: SEC Form D, newest notice filed Feb 8, 2016. Read the notice at the SEC.

debt, optionsSEC
Dec 2013$10 MNo. 6$10 to $50 million

Echo Therapeutics, Inc.: Raise no. 6, Dec 2013

Investors in this round

4 investors had bought by the notice of Dec 19, 2013: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Echo Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Schnittker · Executive Officer
  • Kimberly Burke · Executive Officer
  • Robert Doman · Executive Officer, Director
  • James Smith · Director
  • Vincent Enright · Director
  • William Grieco · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “This amount includes all of the common stock, preferred stock and warrants”

Signed by Kimberly A. Burke, Senior Vice President and General Counsel. Source: SEC Form D, newest notice filed Dec 19, 2013. Read the notice at the SEC.

equity, optionsSEC
Feb 2011$4 MNo. 5$2 to $10 million

Echo Therapeutics, Inc.: Raise no. 5, Feb 2011

Investors in this round

3 investors had bought by the notice of Feb 15, 2011: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Echo Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$500,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry G. Mitchell · Executive Officer
  • Patrick T. Mooney · Executive Officer, Director
  • James F. Smith · Director
  • Shawn K. Singh · Director
  • Vincent D. Enright · Director
  • William F. Grieco · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Harry G. Mitchell, Cfo. Source: SEC Form D, newest notice filed Feb 15, 2011. Read the notice at the SEC.

equity, optionsSEC
Nov 2010$3 MNo. 4$2 to $10 million

Echo Therapeutics, Inc.: Raise no. 4, Nov 2010

Investors in this round

46 investors had bought by the notice of Feb 15, 2011: 46 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Echo Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered; $0 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$65,625
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry G. Mitchell · Executive Officer
  • Patrick T. Mooney · Executive Officer, Director
  • James F. Smith · Director
  • Shawn K. Singh · Director
  • Vincent D. Enright · Director
  • William F. Grieco · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LifeTech Capital, a division of Aurora Capital, LLC (CRD 37924) · New York, New YorkSold in FL, IL, PA, and outside the US
  • Monarch Capital Group, LLC · New York, New YorkSold in CA, FL, MA, MN, PA

Signed by Harry G. Mitchell, Cfo. Source: SEC Form D, newest notice filed Feb 15, 2011. Read the notice at the SEC.

equity, optionsSEC
Feb 2010$2 MNo. 3$2 to $10 million

Echo Therapeutics, Inc.: Raise no. 3, Feb 2010

Investors in this round

38 investors had bought by the notice of Oct 21, 2010: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Echo Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$140,335
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry Mitchell · Executive Officer
  • Patrick Mooney · Executive Officer, Director
  • Shawn Singh · Director
  • Vincent Enright · Director
  • Walter Witoshkin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BOENNING & SCATTERGOOD, INC. (CRD 100) · West Conshohocken, PennsylvaniaSold in CA, CT, IL, ME, PA
  • BURNHAM HILL PARTNERS LLC (CRD 148000) · New York, New YorkSold in CA, CO, IL, MD, NY

Remarks in the notice

  • On fees: “Includes $5,000 expense reimbursement.”

Signed by Harry G. Mitchell, Cfo. Source: SEC Form D, newest notice filed Oct 21, 2010. Read the notice at the SEC.

equity, optionsSEC
Nov 2009$3 MNo. 2$2 to $10 million

Echo Therapeutics, Inc.: Raise no. 2, Nov 2009

Investors in this round

8 investors had bought by the notice of Nov 20, 2009: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Echo Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
$56,250
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$154,438
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry Mitchell · Executive Officer
  • Patrick Mooney · Executive Officer, Director
  • Robert Langer · Director
  • Shawn Singh · Director
  • Vincent Enright · Director
  • Walter Witoshkin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BURNHAM HILL PARTNERS (CRD 148000) · New York, NySold in no state named

Remarks in the notice

  • On the amounts: “$805,070 of the amount sold was comprised of non-cash proceeds related to (i) the extinguishment of a Note and (ii) the investment of funds payable by the Company to the investor for a mandatory preferred stock redemption upon closing of this offering.”

Signed by Harry G. Mitchell, Cfo. Source: SEC Form D, newest notice filed Nov 20, 2009. Read the notice at the SEC.

equity, optionsSEC
Jul 2009$2 MNo. 1$2 to $10 million

Echo Therapeutics, Inc.: Raise no. 1, Jul 2009

Investors in this round

1 investor had bought by the notice of Jul 28, 2009: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Echo Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$2,000,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry Mitchell · Executive Officer
  • Kimberly Burke · Executive Officer
  • Patrick Mooney · Executive Officer, Director
  • Robert Langer · Director
  • Shawn Singh · Director
  • Vincent Enright · Director
  • Walter Witoshkin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BURNHAM HILL PARTNERS (CRD 148000) · New York, NySold in no state named

Signed by Harry G. Mitchell, Cfo. Source: SEC Form D, newest notice filed Jul 28, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Echo Therapeutics, Inc. had no revenue when it filed its newest notice of a funding round (Feb 2016).

    SEC Form D (revenue range) · Feb 2016

  • Revenue range over time, as stated in its notices: revenue of up to $1 million in 2010; revenue of up to $1 million in 2011; revenue of up to $1 million in 2013; no revenue in 2016.

    SEC Form D (revenue range) · Feb 2016

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Feb 2016

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Echo Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Platinum Long Term Growth VII, LLCOthernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Platinum Management (NY) LLCFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Platinum-Montaur Life Sciences, LLCOthernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Platinum Partners Liquid Opportunity Master Fund L.P.Fund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Platinum Partners Value Arbitrage Fund, LPFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 46 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Echo Therapeutics, Inc.
NameRoleNamed in
Alan W. SchoenbartExecutive officerFeb 2016
Scott W. HollanderExecutive officerFeb 2016
Christopher SchnittkerExecutive officerDec 2013
Kimberly BurkeExecutive officerDec 2013
Robert DomanExecutive officerDec 2013
Harry G. MitchellExecutive officerFeb 2011
Patrick T. MooneyExecutive officerFeb 2011
Harry MitchellExecutive officerOct 2010
Patrick MooneyExecutive officerOct 2010
Elazer R. EdelmanDirectorFeb 2016
Michael M. GoldbergDirectorFeb 2016
Scott W. HollanderDirectorFeb 2016
Shepard M. GoldbergDirectorFeb 2016
James SmithDirectorDec 2013
Robert DomanDirectorDec 2013
Vincent EnrightDirectorDec 2013
William GriecoDirectorDec 2013
James F. SmithDirectorFeb 2011
Patrick T. MooneyDirectorFeb 2011
Shawn K. SinghDirectorFeb 2011
Vincent D. EnrightDirectorFeb 2011
William F. GriecoDirectorFeb 2011
Patrick MooneyDirectorOct 2010
Shawn SinghDirectorOct 2010
Walter WitoshkinDirectorOct 2010
Robert LangerDirectorNov 2009